Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

di Melosky, B., Agulnik, J., Assi, H.
Pubblicazione 2008

The Peter Brojde Lung Cancer Centre: a model of integrative practice

di Grossman, M., Agulnik, J., Batist, G.
Pubblicazione 2012

Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers

di Gagnon, B, Agulnik, J S, Gioulbasanis, I, Kasymjanova, G, Morris, D, MacDonald, N
Pubblicazione 2013

Effectiveness of antigliadin antibodies as a screening test for celiac disease in children

di Chartrand, L J, Agulnik, J, Vanounou, T, Russo, P A, Baehler, P, Seidman, E G
Pubblicazione 1997

The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study

di Kasymjanova, G., Grossman, M., Tran, T., Jagoe, R.T., Cohen, V., Pepe, C., Small, D., Agulnik, J.
Pubblicazione 2013

An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world pra...

di Ma, K., Cohen, V., Kasymjanova, G., Small, D., Novac, K., Peterson, J., Levit, A., Agulnik, J.
Pubblicato in Curr Oncol (2015)

The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer

di Kasymjanova, G., MacDonald, N., Agulnik, J.S., Cohen, V., Pepe, C., Kreisman, H., Sharma, R., Small, D.
Pubblicazione 2010

Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients?

di Kasymjanova, G., Jagoe, R.T., Pepe, C., Sakr, L., Cohen, V., Small, D., Muanza, T.M., Agulnik, J.S.
Pubblicato in Curr Oncol (2018)

Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec

di Agulnik, J., Kasymjanova, G., Pepe, C., Hurry, M., Walton, R.N., Sakr, L., Cohen, V., Lecavalier, M., Small, D.
Pubblicato in Curr Oncol (2020)

Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes

di Kasymjanova, G., Small, D., Cohen, V., Jagoe, R.T., Batist, G., Sateren, W., Ernst, P., Pepe, C., Sakr, L., Agulnik, J.
Pubblicato in Curr Oncol (2017)

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

di Melosky, B., Agulnik, J., Albadine, R., Banerji, S., Bebb, D.G., Bethune, D., Blais, N., Butts, C., Cheema, P., Cheung, P., Cohen, V., Deschenes, J., Ionescu, D.N., Juergens, R., Kamel-Reid, S., Laurie, S.A., Liu, G., Morzycki, W., Tsao, M.S., Xu, Z., Hirsh, V.
Pubblicato in Curr Oncol (2016)

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

di Melosky, B., Cheema, P., Agulnik, J., Albadine, R., Bebb, D.G., Blais, N., Burkes, R., Butts, C., Card, P.B., Chan, A.M.Y., Hirsh, V., Ionescu, D.N., Juergens, R., Morzycki, W., Poonja, Z., Sangha, R., Tehfe, M., Tsao, M.S., Vincent, M., Xu, Z., Liu, G.
Pubblicato in Curr Oncol (2018)

Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective

di Bebb, D.G., Agulnik, J., Albadine, R., Banerji, S., Bigras, G., Butts, C., Couture, C., Cutz, J.C., Desmeules, P., Ionescu, D.N., Leighl, N.B., Melosky, B., Morzycki, W., Rashid-Kolvear, F., Lab, Clin, Sekhon, H.S., Smith, A.C., Stockley, T.L., Torlakovic, E., Xu, Z., Tsao, M.S.
Pubblicato in Curr Oncol (2019)